Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | CHKA | P35790 | 1/20 | 0.39 |
| ▸ | HTR7 | P34969 | 1/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 8/20 | 0.37 |
| ▸ | PDE2A | O00408 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.35 |
| ▸ | DDR1 | Q08345 | 2/20 | 0.35 |
| ▸ | ACHE | P22303 | 1/20 | 0.35 |
| ▸ | GFER | P55789 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4289837 | 0.81 | CHKA (0.55) | KDM4EALDH1A1TDP1CHKAPDE2A | |
| SCHEMBL3397376 | 0.81 | GFER (0.51) | KDM4EALDH1A1CHKAPDE2APOLB | |
| SCHEMBL19211675 | 0.81 | CHKA (0.40) | KDM4EALDH1A1TDP1CHKAHRH3 | |
| SCHEMBL20680179 | 0.80 | KDM4E (0.45) | KDM4EALDH1A1TDP1HTR7POLB | |
| SCHEMBL18704978 | 0.80 | ALDH1A1 (0.57) | KDM4EALDH1A1TDP1POLBTSHR | |
| SCHEMBL2106701 | 0.79 | ALDH1A1 (0.46) | KDM4EALDH1A1TDP1CHKAHRH3 | |
| SCHEMBL1427472 | 0.78 | ALDH1A1 (0.49) | KDM4EALDH1A1TDP1CHKAHRH3 | |
| SCHEMBL4296929 | 0.76 | L3MBTL1 (0.51) | KDM4EALDH1A1TDP1HRH3 | |
| SCHEMBL19211650 | 0.75 | ACHE (0.41) | KDM4EALDH1A1TDP1HRH3SOS1 | |
| SCHEMBL4048591 | 0.75 | KDM4E (0.55) | KDM4EALDH1A1TDP1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8420657-B2 | Pyrrolo[2,3-D]pyrimidines and use thereof as tyrosine kinase inhibitors | NOVARTIS AG (CH) | 2013-04-16 | — | — | US | disclosed |
| US-20090203688-A1 | HETEROCYCLIC COMPOUNDS | NOVARTIS AG | 2009-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090203688-A1 | HETEROCYCLIC COMPOUNDS | ABL1, JAK2, JAK1 | KDM4E 1741/4885ALDH1A1 1389/4885TDP1 1871/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.